Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 6Nausea 3Neoplasms 2Uterine Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 63Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 24Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14durvalumab 11Nivolumab 11rucaparib 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × fosaprepitant × Clear all
NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡